Literature DB >> 1551701

Glucocorticoids inhibit granulocyte-macrophage colony-stimulating factor-1 and interleukin-5 enhanced in vitro survival of human eosinophils.

M P Hallsworth1, T M Litchfield, T H Lee.   

Abstract

The effects of three corticosteroids, hydrocortisone, dexamethasone and methylprednisolone, on eosinophil survival enhanced by recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) and recombinant murine interleukin-5 (rmIL-5) have been studied. Eosinophils were incubated at a concentration of 5 x 10(5) cells/ml in the presence of different concentrations of the three steroids with either rhGM-CSF (1 ng/ml) or rmIL-5 (50 U/ml). The eosinophils were cultured in the presence of the same concentrations of rhGM-CSF and rmIL-5 alone as a positive control and medium alone as a negative control. Viability was assessed after 7 days by trypan blue exclusion. All three steroids inhibited rhGM-CSF-enhanced eosinophil survival in a dose-dependent manner; the dose of these drugs producing 50% inhibition (IC50) was greater than 1.0 x 10(-4) M, 6.5 x 10(-6) M and 1.8 x 10(-6) M for hydrocortisone, dexamethasone and methylprednisolone, respectively. When eosinophils were cultured with the same concentration of rhGM-CSF in the presence of two non-glucocorticoids, beta-oestradiol and testosterone, neither of these steroids inhibited eosinophil survival over the concentration range 1 x 10(-10) M to 1 x 10(-4) M (n = 5). Dexamethasone and methylprednisolone, but not hydrocortisone, also inhibited eosinophil survival induced by rmIL-5 in a dose-dependent manner. These results suggest one mechanism for the efficacy of corticosteroids against eosinophil-related disorders.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1551701      PMCID: PMC1384724     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  23 in total

1.  Changes in circulating leukocytes following the administration of adrenal cortex extract (ACE) and adrenocorticotropic hormone (ACTH) in infectious mononucleosis and chronic lymphatic leukemia.

Authors:  R H SAUNDERS; E ADAMS
Journal:  Blood       Date:  1950-08       Impact factor: 22.113

2.  Interleukin 5 is required for the blood and tissue eosinophilia but not granuloma formation induced by infection with Schistosoma mansoni.

Authors:  A Sher; R L Coffman; S Hieny; P Scott; A W Cheever
Journal:  Proc Natl Acad Sci U S A       Date:  1990-01       Impact factor: 11.205

3.  Glucocorticoids inhibit eosinophil responses to granulocyte-macrophage colony-stimulating factor.

Authors:  A M Lamas; O G Leon; R P Schleimer
Journal:  J Immunol       Date:  1991-07-01       Impact factor: 5.422

4.  A new method for the purification of human eosinophils and neutrophils, and a comparison of the ability of these cells to damage schistosomula of Schistosoma mansoni.

Authors:  M A Vadas; J R David; A Butterworth; N T Pisani; T A Siongok
Journal:  J Immunol       Date:  1979-04       Impact factor: 5.422

5.  In vitro and in vivo studies with purified recombinant human interleukin 5.

Authors:  D Fattah; D J Quint; A Proudfoot; R O'Malley; E D Zanders; B R Champion
Journal:  Cytokine       Date:  1990-03       Impact factor: 3.861

6.  Identification of an alveolar macrophage-derived activity in bronchial asthma that enhances leukotriene C4 generation by human eosinophils stimulated by ionophore A23187 as a granulocyte-macrophage colony-stimulating factor.

Authors:  C J Howell; J L Pujol; A E Crea; R Davidson; A J Gearing; P Godard; T H Lee
Journal:  Am Rev Respir Dis       Date:  1989-11

7.  Identification of the major activity derived from cultured human peripheral blood mononuclear cells, which enhances eosinophil viability, as granulocyte macrophage colony-stimulating factor (GM-CSF).

Authors:  L A Burke; M P Hallsworth; T M Litchfield; R Davidson; T H Lee
Journal:  J Allergy Clin Immunol       Date:  1991-08       Impact factor: 10.793

Review 8.  Glucocorticosteroid therapy: mechanisms of action and clinical considerations.

Authors:  A S Fauci; D C Dale; J E Balow
Journal:  Ann Intern Med       Date:  1976-03       Impact factor: 25.391

9.  Human endothelial cells prolong eosinophil survival. Regulation by cytokines and glucocorticoids.

Authors:  A M Lamas; G V Marcotte; R P Schleimer
Journal:  J Immunol       Date:  1989-06-01       Impact factor: 5.422

10.  Regulation of parasite-induced eosinophilia: selectively increased interleukin 5 production in helminth-infected patients.

Authors:  A P Limaye; J S Abrams; J E Silver; E A Ottesen; T B Nutman
Journal:  J Exp Med       Date:  1990-07-01       Impact factor: 14.307

View more
  10 in total

Review 1.  Cytokines in asthma.

Authors:  K F Chung; P J Barnes
Journal:  Thorax       Date:  1999-09       Impact factor: 9.139

Review 2.  Recent advances in asthma.

Authors:  P J Barnes; T H Lee
Journal:  Postgrad Med J       Date:  1992-12       Impact factor: 2.401

3.  Sinusoidal obstructive syndrome with hypereosinophilia successfully treated with prednisolone.

Authors:  Yuichi Yamaga; Yukio Tsugihashi; Takefumi Nakamura; Takanori Taniguchi; Gen Honjou; Masayoshi Kage
Journal:  Clin J Gastroenterol       Date:  2011-11-12

4.  Effect of inhaled steroids on airway hyperresponsiveness, sputum eosinophils, and exhaled nitric oxide levels in patients with asthma.

Authors:  E L van Rensen; K C Straathof; M A Veselic-Charvat; A H Zwinderman; E H Bel; P J Sterk
Journal:  Thorax       Date:  1999-05       Impact factor: 9.139

5.  Effect of differing doses of inhaled budesonide on markers of airway inflammation in patients with mild asthma.

Authors:  A Jatakanon; S Kharitonov; S Lim; P J Barnes
Journal:  Thorax       Date:  1999-02       Impact factor: 9.139

6.  Interleukin-3-induced up-regulation of CR3 expression on human eosinophils is inhibited by dexamethasone.

Authors:  A Hartnell; A B Kay; A J Wardlaw
Journal:  Immunology       Date:  1992-12       Impact factor: 7.397

7.  The Eosinophil Count Tends to Be Negatively Associated with Levels of Serum Glucose in Patients with Adrenal Cushing Syndrome.

Authors:  Younghak Lee; Hyon Seung Yi; Hae Ri Kim; Kyong Hye Joung; Yea Eun Kang; Ju Hee Lee; Koon Soon Kim; Hyun Jin Kim; Bon Jeong Ku; Minho Shong
Journal:  Endocrinol Metab (Seoul)       Date:  2017-09

8.  Methylxanthine Treatment in Patients Hospitalized for Acute Exacerbation of Chronic Obstructive Pulmonary Disease in China: A Real-World Study Using Propensity Score Matching Analysis.

Authors:  Zijie Zhan; Yiming Ma; Ke Huang; Chen Liang; Xihua Mao; Yaowen Zhang; Xiaoxia Ren; Jieping Lei; Yan Chen; Ting Yang; Chen Wang
Journal:  Front Pharmacol       Date:  2022-01-25       Impact factor: 5.810

9.  Disseminated strongyloidiasis complicating glioblastoma therapy: a case report.

Authors:  Dawit Aregawi; David Lopez; Mark Wick; W Michael Scheld; David Schiff
Journal:  J Neurooncol       Date:  2009-03-31       Impact factor: 4.506

Review 10.  Anemia, intractable vomiting, chronic diarrhea, and syndrome of inappropriate antidiuretic secretion: a diagnostic dilemma: Disseminated strongyloidosis in a patient with newly diagnosed HTLV infection-case report and review of literature.

Authors:  Hassan Tariq; Muhammad Umar Kamal; Pavithra Reddy; Bharat Bajantri; Masooma Niazi; Ajsza Matela; Cosmina Zeana; Ariyo Ihimoyan; Anil Dev; Sridhar Chilimuri
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.889

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.